article thumbnail

STAT+: Pharmalittle: We’re reading about copycat weight loss drugs, ADHD prescriptions spiking, and more

STAT

Food and Drug Administration wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have other plans , The Wall Street Journal writes. In 2016, Ionis won approval for an infusion called Spinraza.

article thumbnail

STAT+: Pharmalittle: We’re reading about FDA guidance on AI, meds releasing ‘forever chemicals,’ and more

STAT

As of last October, the agency had received more than 500 drug submissions with AI components going back to 2016, with a large number in the areas of oncology, neurology, and gastroenterology.   Most of the compounds came from commonly prescribed medications including antidepressants and statins.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Extemporaneous Compounding

RX Note

Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. NOTE: When compounding a preparation using the contents of an ampoule , care should be taken to withdraw the solution using a filter needle to avoid incorporating glass particles into the compound.

article thumbnail

MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPO

pharmaphorum

Founded in 2016 by husband and wife entrepreneur team George Goldsmith and Ekaterina Malievskaia, Compass is already backed by investors including PayPal co-founder Peter Thiel and German entrepreneur Christian Angermayer. million with its IPO on Friday and shares are still significantly above their launch price of $17.

article thumbnail

Health Innovators: Owlstone Medical’s Billy Boyle on breath biopsy technology

pharmaphorum

Owlstone is developing a breath-based analyser that captures Volatile Organic Compounds (VOCs) in breath non-invasively, and analyses them with high sensitivity. After recognising the potential of the technology to be applied in healthcare, Boyle spun Owlstone Medical out in 2016 and now has a a team of over 170 people.

article thumbnail

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

pharmaphorum

Founded in 2016 as a spin-out from Wuerzburg University, CatalYm’s lead molecule CTL-002 is designed to neutralise the tumour-produced protein GDF-15. CatalYm will also test the compound in combination with approved checkpoint blockers. The company is expecting to be at clinical stage by the end of the year.

Immunity 105
article thumbnail

Roche rings Bicycle bell again, grabbing another cancer target

pharmaphorum

Bicycle said that none of the compounds in its in-house oncology pipeline, including its immuno-oncology candidates, are included in the Genentech collaboration. Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7

Immunity 105